Penumbra’s chief medical officer James Benenati said the device can help reduce costs in healthcare systems. Image credit: Shutterstock / Chawalit Banpot.

Penumbra has posted positive data for its computer-assisted vacuum thrombectomy (CAVT) technology aimed at treating patients with intermediate-risk pulmonary embolism (PE).

The US company reported that patients treated with its Lightning Flash or Lightning 12 technology experienced shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options. Penumbra presented the results at the Vascular Interventional Advances (VIVA) 2024 conference in Las Vegas.

Related Company Profiles

View all

The data comes from a retrospective study that analysed 2,060 adult inpatients with intermediate-risk PE. Resource use and health outcomes with Penumbra’s tech were pitted against standard procedures such as anticoagulation, catheter-directed thrombolysis or other mechanical thrombectomy devices.

Thrombectomy is a surgical procedure that typically uses a catheter to remove blood clots from vessels.

Penumbra has developed a microprocessor with thrombus removal algorithms that, combined with audio-visual feedback, help streamline clot removal. According to the company, the US Food and Drug Administration (FDA)-cleared Lightning CAVT technology uses both pressure and flow-based processes to detect blood clots and blood flow.

Along with hospital resource and stay reductions, Penumbrasaid in-hospital mortality was low with CAVT, with no significant difference in this parameter between treatment options.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Penumbra’s chief medical officer James Benenati said: “With this study, the findings suggest that by increasing patient access to advanced therapies like CAVT, it can also have an important, positive impact on hospital systems by greatly reducing resource utilisation versus other modalities, therefore decreasing the overall cost to the healthcare system.”

The clot management device market was estimated to be worth $4.4bn last year, with it forecast to rise to $7.5bn by 2033, according to analysis by GlobalData. The thrombectomy catheter market is predicted to contribute $3.5bn to the global market by the same year. GlobalData lists Boston Scientific as the manufacturer with the greatest global market share in thrombectomy catheters.

The day before Penumbra announced its results, Inquis Medical – which is also in the thrombectomy space – revealed it had closed a $40m Series B financing round. The company’s lead product, Aventus, features proprietary tissue-sensing technology and provides real-time information on tissue characteristics. In September, AngioDynamics initiated a trial evaluating its thrombectomy system for treating patients with acute PE.